These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 29777171)
1. MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Skucha A; Ebner J; Schmöllerl J; Roth M; Eder T; César-Razquin A; Stukalov A; Vittori S; Muhar M; Lu B; Aichinger M; Jude J; Müller AC; Győrffy B; Vakoc CR; Valent P; Bennett KL; Zuber J; Superti-Furga G; Grebien F Nat Commun; 2018 May; 9(1):1983. PubMed ID: 29777171 [TBL] [Abstract][Full Text] [Related]
2. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins. Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074 [TBL] [Abstract][Full Text] [Related]
3. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Nguyen AT; Taranova O; He J; Zhang Y Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783 [TBL] [Abstract][Full Text] [Related]
4. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential. Kuntimaddi A; Achille NJ; Thorpe J; Lokken AA; Singh R; Hemenway CS; Adli M; Zeleznik-Le NJ; Bushweller JH Cell Rep; 2015 May; 11(5):808-20. PubMed ID: 25921540 [TBL] [Abstract][Full Text] [Related]
5. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907 [TBL] [Abstract][Full Text] [Related]
6. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia. Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180 [TBL] [Abstract][Full Text] [Related]
7. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334 [TBL] [Abstract][Full Text] [Related]
8. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Wang QF; Wu G; Mi S; He F; Wu J; Dong J; Luo RT; Mattison R; Kaberlein JJ; Prabhakar S; Ji H; Thirman MJ Blood; 2011 Jun; 117(25):6895-905. PubMed ID: 21518926 [TBL] [Abstract][Full Text] [Related]
9. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721 [TBL] [Abstract][Full Text] [Related]
10. Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia. Wang WT; Han C; Sun YM; Chen ZH; Fang K; Huang W; Sun LY; Zeng ZC; Luo XQ; Chen YQ Clin Cancer Res; 2019 May; 25(9):2795-2808. PubMed ID: 30651276 [TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL. Yuan Y; Du L; Tan R; Yu Y; Jiang J; Yao A; Luo J; Tang R; Xiao Y; Sun H J Med Chem; 2022 Jun; 65(11):7770-7785. PubMed ID: 35612819 [TBL] [Abstract][Full Text] [Related]
19. SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia. Bu J; Chen A; Yan X; He F; Dong Y; Zhou Y; He J; Zhan D; Lin P; Hayashi Y; Sun Y; Zhang Y; Xiao Z; Grimes HL; Wang QF; Huang G Leukemia; 2018 Apr; 32(4):890-899. PubMed ID: 29249820 [TBL] [Abstract][Full Text] [Related]
20. MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. Kerry J; Godfrey L; Repapi E; Tapia M; Blackledge NP; Ma H; Ballabio E; O'Byrne S; Ponthan F; Heidenreich O; Roy A; Roberts I; Konopleva M; Klose RJ; Geng H; Milne TA Cell Rep; 2017 Jan; 18(2):482-495. PubMed ID: 28076791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]